Aclaris Therapeutics (ACRS) Non-Current Debt (2018 - 2021)
Aclaris Therapeutics (ACRS) posted quarterly Non-Current Debt of $10.7 million for Q2 2021, up 1.49% year-over-year from $10.6 million in Q2 2020, and little changed quarter-over-quarter from $10.7 million in Q1 2021.
Aclaris Therapeutics (ACRS) Non-Current Debt (2018 - 2021) Analysis & Trends
Aclaris Therapeutics' Non-Current Debt history runs 4 years deep, the most recent figure standing at $10.7 million for Q2 2021.
- In Q2 2021, Non-Current Debt rose 1.49% year-over-year to $10.7 million; the TTM figure through Jun 2021 stood at $10.7 million (up 1.49% YoY), while the FY2020 annual figure was $10.7 million, changed N/A from the prior year.
- Non-Current Debt for Q2 2021 stood at $10.7 million, roughly flat from $10.7 million in the prior quarter.
- The five-year high for Non-Current Debt was $29.9 million in Q3 2019, with the low at $10.6 million in Q1 2020.
- The 4-year median for Non-Current Debt is $10.7 million (2021), against an average of $18.4 million.
- The sharpest annual moves came in 2020 and 2021: Non-Current Debt plunged 64.67% in 2020, then advanced 1.49% in 2021.
- Aclaris Therapeutics' Non-Current Debt stood at $29.9 million in 2018, then grew by 0.05% to $29.9 million in 2019, then plunged by 64.41% to $10.7 million in 2020, then grew by 0.73% to $10.7 million in 2021.
- Business Quant data shows ACRS's Non-Current Debt at $10.7 million in Q2 2021, $10.7 million in Q1 2021, and $10.7 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 10.73 Mn |
| Mar 31, 2021 | 10.69 Mn |
| Dec 31, 2020 | 10.65 Mn |
| Sep 30, 2020 | 10.61 Mn |
| Jun 30, 2020 | 10.57 Mn |
| Mar 31, 2020 | 10.57 Mn |
| Sep 30, 2019 | 29.93 Mn |
| Jun 30, 2019 | 29.92 Mn |
| Mar 31, 2019 | 29.92 Mn |
| Dec 31, 2018 | 29.91 Mn |